Static platelet adhesion, flow cytometry and serum TXB2 levels for monitoring platelet inhibiting treatment with ASA and clopidogrel in coronary artery disease: A randomised cross-over study

Journal of Translational Medicine

Volumn 7, Issue , 2009, Pages

  Eriksson, Andreas C ^a   Jonasson, Lena ^a   Lindahl, Tomas L ^b   Hedbäck, Bo ^a   Whiss, Per A ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ALBUMIN; CLOPIDOGREL; COLLAGEN; THROMBOXANE B2; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; FIBRINOGEN; PADGEM PROTEIN; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; MONOTHERAPY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE ADHESION; THROMBOCYTE FUNCTION; BLOOD; CASE CONTROL STUDY; DRUG EFFECT; HEALTH; METABOLISM; MIDDLE AGED; PRINCIPAL COMPONENT ANALYSIS; REGRESSION ANALYSIS; THROMBOCYTE ADHESIVENESS;

AGED; ASPIRIN; CASE-CONTROL STUDIES; CORONARY DISEASE; CROSS-OVER STUDIES; FEMALE; FIBRINOGEN; FLOW CYTOMETRY; HEALTH; HUMANS; MALE; MIDDLE AGED; P-SELECTIN; PLATELET ADHESIVENESS; PLATELET AGGREGATION INHIBITORS; PRINCIPAL COMPONENT ANALYSIS; REGRESSION ANALYSIS; THROMBOXANE B2; TICLOPIDINE;

EID: 67649601043     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-7-42     Document Type: Article

References (53)

1. Antiplatelet Trialists' Collaboration Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ 1994, 308:81-106 2539220 8298418
2. CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet 1996, 348:1329-1339 10.1016/S0140-6736(96)09457-3 8918275
3. Yusuf S Zhao F Mehta SR Chrolavicius S Tognoni G Fox KK Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 2001, 345:494-502 10.1056/NEJMoa010746 11519503
4. Chen ZM Jiang LX Chen YP Xie JX Pan HC Peto R Collins R Liu LS Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: Randomised placebo-controlled trial Lancet 2005, 366:1607-1621 10.1016/S0140-6736(05)67660-X 16271642
5. Sabatine MS Cannon CP Gibson CM Lopez-Sendon JL Montalescot G Theroux P Claeys MJ Cools F Hill KA Skene AM McCabe CH Braunwald E Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation N Engl J Med 2005, 352:1179-1189 10.1056/NEJMoa050522 15758000
6. Steinhubl SR Berger PB Mann JT 3rd Fry ET DeLago A Wilmer C Topol EJ Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial JAMA 2002, 288:2411-2420 10.1001/jama.288.19.2411 12435254
7. Mehta SR Yusuf S Peters RJ Bertrand ME Lewis BS Natarajan MK Malmberg K Rupprecht H Zhao F Chrolavicius S Copland I Fox KA Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study Lancet 2001, 358:527-533 10.1016/S0140-6736(01)05701-4 11520521
8. Angiolillo DJ Fernandez-Ortiz A Bernardo E Alfonso F Macaya C Bass TA Costa MA Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives J Am Coll Cardiol 2007, 49:1505-1516 10.1016/j.jacc.2006.11.044 17418288
9. Serebruany VL Steinhubl SR Berger PB Malinin AI Bhatt DL Topol EJ Variability in platelet responsiveness to clopidogrel among 544 individuals J Am Coll Cardiol 2005, 45:246-251 10.1016/ j.jacc.2004.09.067 15653023
10. Jaremo P Lindahl TL Fransson SG Richter A Individual variations of platelet inhibition after loading doses of clopidogrel J Intern Med 2002, 252:233-238 10.1046/j.1365-2796.2002.01027.x 12270003
11. Sanderson S Emery J Baglin T Kinmonth AL Narrative review: Aspirin resistance and its clinical implications Ann Intern Med 2005, 142:370-380 15738456
12. Hankey GJ Eikelboom JW Aspirin resistance Lancet 2006, 367:606-617 10.1016/S0140-6736(06)68040-9 16488805
13. Mason PJ Jacobs AK Freedman JE Aspirin resistance and atherothrombotic disease J Am Coll Cardiol 2005, 46:986-993 10.1016/j.jacc.2004.08.070 16168280
14. Harrison P Frelinger AL 3rd Furman MI Michelson AD Measuring antiplatelet drug effects in the laboratory Thromb Res 2007, 120:323-336 10.1016/j.thromres.2006.11.012 17239428
15. Michelson AD Platelet function testing in cardiovascular diseases Circulation 2004, 110:e489-493 10.1161/01.CIR.0000147228.29325.F9 15533872
16. Haubelt H Anders C Hellstern P Can platelet function tests predict the clinical efficacy of aspirin? Semin Thromb Hemost 2005, 31:404-410 10.1055/s-2005-916674 16149017
17. Cannon CP McLean DS Critical pathways using platelet testing to potentially optimize the use of oral antiplatelet therapy Am J Cardiol 2006, 98:10A-33N 38N 17097416 10.1016/j.amjcard.2006.09.012
18. Rand ML Leung R Packham MA Platelet function assays Transfus Apher Sci 2003, 28:307-317 10.1016/S1473-0502(03)00050-8 12725958
19. Michelson AD Cattaneo M Eikelboom JW Gurbel P Kottke-Marchant K Kunicki TJ Pulcinelli FM Cerletti C Rao AK Aspirin resistance: Position paper of the Working Group on Aspirin Resistance J Thromb Haemost 2005, 3:1309-1311 10.1111/j.1538-7836.2005.01351.x 15892858
20. Bonello L Camoin-Jau L Armero S Com O Arques S Burignat-Bonello C Giacomoni MP Bonello R Collet F Rossi P Barragan P Dignat-George F Paganelli F Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis Am J Cardiol 2009, 103:5-10 10.1016/j.amjcard.2008.08.048 19101221
21. Bonello L Camoin-Jau L Arques S Boyer C Panagides D Wittenberg O Simeoni MC Barragan P Dignat-George F Paganelli F Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study J Am Coll Cardiol 2008, 51:1404-1411 10.1016/j.jacc.2007.12.044 18387444
22. Berndt MC Shen Y Dopheide SM Gardiner EE Andrews RK The vascular biology of the glycoprotein Ib-IX-V complex Thromb Haemost 2001, 86:178-188 11487006
23. Eriksson AC Whiss PA Characterization of static adhesion of human platelets in plasma to protein surfaces in microplates Blood Coagul Fibrinolysis 2009, 20:197-206 10.1097/MBC.0b013e328327353d
24. Siess W Athero- and thrombogenic actions of lysophosphatidic acid and sphingosine-1-phosphate Biochim Biophys Acta 2002, 1582:204-215 12069830
25. Eriksson AC Whiss PA Nilsson UK Adhesion of human platelets to albumin is synergistically increased by lysophosphatidic acid and adrenaline in a donor-dependent fashion Blood Coagul Fibrinolysis 2006, 17:359-368 10.1097/01.mbc.0000233366.18605.b2 16788312
26. Graff J Klinkhardt U Harder S Pharmacodynamic profile of antiplatelet agents: Marked differences between single versus costimulation with platelet activators Thromb Res 2004, 113:295-302 10.1016/ j.thromres.2004.03.014 15183041
27. Eriksson AC Whiss PA Measurement of adhesion of human platelets in plasma to protein surfaces in microplates J Pharmacol Toxicol Methods 2005, 52:356-365 10.1016/j.vascn.2005.06.002 16005248
28. Eriksson AC Nilsson UK Whiss PA The extracellular ion environment modulates platelet adhesion after lysophosphatidic acid treatment in vitro [abstract] Atheroscler Suppl 2006 7(s90) 10.1016/ S1567-5688(06)80335-1
29. Nylander S Johansson K Van Giezen JJ Lindahl TL Evaluation of platelet function, a method comparison Platelets 2006, 17:49-55 10.1080/ 09537100500197448 16308187
30. Lundahl TH Petersson J Fagerberg IH Berg S Lindahl TL Impaired platelet function correlates with multi-organ dysfunction. A study of patients with sepsis Platelets 1998, 9:223-225 10.1080/09537109876735 16793706
31. Lindahl TL Festin R Larsson A Studies of fibrinogen binding to platelets by flow cytometry: An improved method for studies of platelet activation Thromb Haemost 1992, 68:221-225 1412170
32. Berglund U Lindahl T Enhanced onset of platelet inhibition with a loading dose of ticlopidine in ASA-treated stable coronary patients Int J Cardiol 1998, 64:215-217 10.1016/S0167-5273(98)00023-0 9688443
33. Cayman Chemical EIA Analysis Tools http://www.caymanchem.com/analysis/eia
34. Bryman A Cramer D Aggregating variables Exploratory factor analysis Quantitative Data Analysis with SPSS Release 8 for Windows: For Social Scientists London: Routledge Bryman A, Cramer D 1 1999, 271-285
35. Eriksson AC Jonasson L Hedback B Whiss PA Monitoring platelet inhibiting treatment in coronary heart disease by static platelet adhesion [abstract] Atheroscler Suppl 2007, 8:s189 10.1016/S1567-5688(07)71719-1
36. Fimognari FL Piccirillo G Lama J Paganica P Monteleone G Gianni W Cacciafesta M Marigliano V Associated daily biosynthesis of cortisol and thromboxane A2: A preliminary report J Lab Clin Med 1996, 128:115-121 10.1016/S0022-2143(96)90120-1 8759943
37. Mustad V Derr J Reddy CC Pearson TA Kris-Etherton PM Seasonal variation in parameters related to coronary heart disease risk in young men Atherosclerosis 1996, 126:117-129 10.1016/0021-9150(96)05900-X 8879440
38. Grewe PH Deneke T Machraoui A Barmeyer J Muller KM Acute and chronic tissue response to coronary stent implantation: Pathologic findings in human specimen J Am Coll Cardiol 2000, 35:157-163 10.1016/ S0735-1097(99)00486-6 10636274
39. Joner M Finn AV Farb A Mont EK Kolodgie FD Ladich E Kutys R Skorija K Gold HK Virmani R Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk J Am Coll Cardiol 2006, 48:193-202 10.1016/j.jacc.2006.03.042 16814667
40. Khovidhunkit W Memon RA Feingold KR Grunfeld C Infection and inflammation-induced proatherogenic changes of lipoproteins J Infect Dis 2000, 181(Suppl 3):S462-S472 10839741 10.1086/315611
41. von Ruecker A Hufnagel P Dickerhoff R Murday H Bidlingmaier F Qualitative and quantitative changes in platelets after coronary-artery bypass surgery may help identify thrombotic complications and infections Klin Wochenschr 1989, 67:1042-1047 10.1007/BF01727006 2586010
42. Moreau D Timsit JF Vesin A Garrouste-Orgeas M de Lassence A Zahar JR Adrie C Vincent F Cohen Y Schlemmer B Azoulay E Platelet count decline: an early prognostic marker in critically ill patients with prolonged ICU stays Chest 2007, 131:1735-1741 10.1378/chest.06-2233 17475637
43. Pizzulli L Yang A Martin JF Luderitz B Changes in platelet size and count in unstable angina compared to stable angina or non-cardiac chest pain Eur Heart J 1998, 19:80-84 10.1053/euhj.1997.0747 9503179
44. Frelinger AL 3rd Furman MI Linden MD Li Y Fox ML Barnard MR Michelson AD Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: A 700-patient study of aspirin resistance Circulation 2006, 113:2888-2896 10.1161/ CIRCULATIONAHA.105.596627 16785341
45. Rao GH Michiels JJ Aspirin resistance: Does it exist? Semin Thromb Hemost 2007, 33:210-214 10.1055/s-2007-969036 17340471
46. Kawasaki T Ozeki Y Igawa T Kambayashi J Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin Stroke 2000, 31:591-595 10700490
47. Macchi L Christiaens L Brabant S Sorel N Allal J Mauco G Brizard A Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate Thromb Res 2002, 107:45-49 10.1016/ S0049-3848(02)00210-4 12413588
48. Rao GH Escolar G White JG Epinephrine reverses the inhibitory influence of aspirin on platelet-vessel wall interactions Thromb Res 1986, 44:65-74 10.1016/0049-3848(86)90181-7 3787562
49. Hurlen M Seljeflot I Arnesen H Increased platelet aggregability during exercise in patients with previous myocardial infarction. Lack of inhibition by aspirin Thromb Res 2000, 99:487-494 10.1016/ S0049-3848(00)00277-2 10973679
50. Violi F Pignatelli P Pulcinelli FM Aspirin J Thromb Haemost 2004, 2:338-339 10.1111/j.1538-7836.2004.0615d.x 14996001
51. Lasne D Donato J Falet H Rendu F Different abilities of thrombin receptor activating peptide and thrombin to induce platelet calcium rise and full release reaction Thromb Haemost 1995, 74:1323-1328 8607117
52. Kinlough-Rathbone RL Perry DW Guccione MA Rand ML Packham MA Degranulation of human platelets by the thrombin receptor peptide SFLLRN: Comparison with degranulation by thrombin Thromb Haemost 1993, 70:1019-1023 8165594
53. Moshfegh K Redondo M Julmy F Wuillemin WA Gebauer MU Haeberli A Meyer BJ Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: Enhanced inhibitory effects of combination therapy J Am Coll Cardiol 2000, 36:699-705 10.1016/S0735-1097(00)00817-2 10987587